Gastrointestinal stromal tumors and second primary malignancies before and after the introduction of imatinib mesylate

被引：1

作者：

Jacopo Giuliani ^{[1
]}

Andrea Bonetti ^{[1
]}

机构：

[1] Department of Oncology,Mater Salutis Hospital-ASL 21 della Regione Veneto,Legnago (VR),Italy

来源：

Chinese Journal of Cancer Research | 2013年 / 25卷 / 05期

关键词：

GIST; Gastrointestinal stromal tumors and second primary malignancies before and after the introduction of imatinib mesylate;

D O I：

暂无

中图分类号：

R735 [消化系肿瘤];

学科分类号：

100214 ;

摘要：

Gastrointestinal stromal tumor(GIST)is the most common mesenchymal malignancy of the gastrointestinal tract.GISTs may coexist with different types of cancer,either synchronous or metachronous(1).Most GISTs develop in a sporadic fashion,but familial occurrence,such as neurofibromatosis and Carney-triad,has also been reported(2).The overall frequency of second tumors in different series varied from

引用

页码：486 / 487

页数：2

共 50 条

[41] Gastrointestinal stromal tumors: Overview of pathologic features, molecular biology, and therapy with imatinib mesylate
Koh, JS
Trent, J
Chen, L
El-Naggar, A
Hunt, K
Pollock, R
Zhang, W
HISTOLOGY AND HISTOPATHOLOGY, 2004, 19 (02) : 565 - 574
[42] Imatinib mesylate treatment in a dog with gastrointestinal stromal tumors with a c-kit mutation
Irie, Mitsuhiro
Takeuchi, Yoshinori
Ohtakei, Yuzo
Suzukii, Hitomi
Nagata, Nao
Miyoshi, Takuma
Kagawa, Yumiko
Yamagami, Tetsushi
JOURNAL OF VETERINARY MEDICAL SCIENCE, 2015, 77 (11): : 1535 - 1539
[43] Some lessons learned from imatinib mesylate clinical development in gastrointestinal stromal tumors
Casali, PG
Bertulli, R
Fumagalli, E
Coco, P
Grosso, F
Stacchiotti, S
JOURNAL OF CHEMOTHERAPY, 2004, 16 : 55 - 58
[44] Imatinib mesylate activates IGFBP3 expression in gastrointestinal stromal tumors.
Dupart, J
Trent, JC
Cohen, P
Zhang, W
CLINICAL CANCER RESEARCH, 2005, 11 (24) : 8987S - 8987S
[45] Secondary resistance of extra-gastrointestinal stromal tumors to imatinib mesylate: Report of a case
Koji Ando
Eiji Oki
Masahiko Sugiyama
Yan Zhao
Aya Kojima
Hidetaka Yamamoto
Yoichi Yamashita
Hiroshi Saeki
Akinobu Taketomi
Masaru Morita
Yoshihiro Kakeji
Shunichi Tsujitani
Yoshihiko Maehara
Surgery Today, 2011, 41 : 1290 - 1293
[46] Approval summary: Imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors
Dagher, R
Cohen, M
Williams, G
Rothmann, M
Gobburu, J
Robbie, G
Rahman, A
Chen, G
Staten, A
Griebel, D
Pazdur, R
CLINICAL CANCER RESEARCH, 2002, 8 (10) : 3034 - 3038
[47] The role of surgery in the management of gastrointestinal stromal tumors (GISTs) in the era of imatinib mesylate effectiveness
Kosmadakis, N
Visvardis, EE
Kartsaklis, P
Tsimara, M
Chatziantoniou, A
Panopoulos, L
Erato, P
Capsambelis, P
SURGICAL ONCOLOGY-OXFORD, 2005, 14 (02): : 75 - 84
[48] Approval Summary: Imatinib Mesylate in the Treatment of Metastatic and/or Unresectable Malignant Gastrointestinal Stromal Tumors
Cohen, Martin H.
Farrell, Ann
Justice, Robert
Pazdur, Richard
ONCOLOGIST, 2009, 14 (02): : 174 - 180
[49] Surgery of residual disease following imatinib mesylate in advanced gastrointestinal stromal tumors (GIST).
Gronchi, A
Fiore, M
Bertulli, R
Colecchia, M
Tamborini, E
Pilotti, S
Messina, A
Coco, P
Stacchiotti, S
Casali, PG
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 825S - 825S
[50] Evaluation of imatinib mesylate (IM) in patients with large volume gastrointestinal stromal tumors (GISTs)
Byrd, D. M.
Demetri, G. D.
Joensuu, H.
von Mehren, M.
Heinrich, M.
Eisenberg, B.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)

← 1 2 3 4 5 →